State of the Art Oncology in EuropeFont: aaa


Capitolo in lavorazione. Questo capitolo è consultabile in lingua inglese.


1.1 Dati Epidemiologici

1.1.1 Incidenza
1.1.2 Sopravvivenza

1.2 Eziologia e fattori di rischio

1.3 Prevenzione e Screening


2.1 Evidenze molecolari

2.2 Classificazione e varianti istologiche


3.1 Segni e sintomi

 3.2 Procedure diagnostiche

3.2.1 Esami di laboratorio
3.2.2 Tecniche radiologiche e loro indicazione in accordo con il quesito diagnostico

3.3 Diagnosi istopatologica


4.1 Esami di stadiazione


5.1 Fattori prognostici


6.1 Strategia terapeutica e dati generali

6.1.1 Chirurgia

6.2 Trattamento Adiuvante

6.2.1 Radioterapia Adiuvante
6.2.2 Chemioterapia Adiuvante
6.2.3 Trattamenti Combinati in Fase Adiuvante

6.3 Trattamento Neoadiuvante

 6.4 Palliazione

6.4.1 Terapia Fotodinamica
6.4.2 Radioterapia palliativa
6.4.3 Chemoterapia

6.5 Opzioni terapeutiche per il colangiocarcinoma perilare

6.6 Opzioni terapeutiche per il colangiocarcinoma distale

6.7 Opzioni terapeutiche per il colangiocarcinoma periferico

6.8 Trapianto di fegato





Alberts SR, Al-Khatib H, Mahoney MR, Burgart L, Cera PJ, Flynn PJ, et al. Gemcitabine, 5-fluorouracil, and leucovorin in advanced biliary tract and gallbladder carcinoma: a North Central Cancer Treatment Group phase II trial. Cancer 2005; 103: 111-118 [Medline]

Alden ME, Mohiuddin M. The impact of radiation dose in combined external beam and intraluminal Ir-192 brachytherapy for bile duct cancer. Int J Radiat Oncol Biol Phys 1994; 28: 945-951 [Medline]

Anderson CD, Rice MH, Pinson CW, Chapman WC, Chari RS, Delbeke D. Fluorodeoxyglucose PET imaging in the evaluation of gallbladder carcinoma and cholangiocarcinoma. J Gastrointest Surg 2004; 8: 90-97 [Medline]

Andre T, Tournigand C, Rosmorduc O, Provent S, Maindrault-Goebel F, Avenin D, et al. Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study. Ann Oncol 2004; 15: 1339-1343 [Medline]

Ben-Menachem T. Risk factors for cholangiocarcinoma. Eur J Gastroenterol Hepatol 2007; 19: 615-617 [Medline]

Bergquist A, Glaumann H, Persson B, Broome U. Risk factors and clinical presentation of hepatobiliary carcinoma in patients with primary sclerosing cholangitis: a case-control study. Hepatology 1998; 27: 311-316 [Medline]

Berr F. Photodynamic therapy for cholangiocarcinoma. Semin Liver Dis 2004; 24: 177-187 [Medline]

Broome U, Olsson R, Loof L, Bodemar G, Hultcrantz R, Danielsson A, et al. Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis. Gut 1996; 38: 610-615 [Medline]

Burak K, Angulo P, Pasha TM, Egan K, Petz J, Lindor KD. Incidence and risk factors for cholangiocarcinoma in primary sclerosing cholangitis. Am J Gastroenterol 2004; 99: 523-526 [Medline]

Burke EC, Jarnagin WR, Hochwald SN, Pisters PW, Fong Y, Blumgart LH. Hilar Cholangiocarcinoma: patterns of spread, the importance of hepatic resection for curative operation, and a presurgical clinical staging system. Ann Surg 1998; 228: 385-394 [Medline]

Carriaga MT, Henson DE. Liver, gallbladder, extrahepatic bile ducts, and pancreas. Cancer 1995; 75: 171-190 [Medline]

Casavilla FA, Marsh JW, Iwatsuki S, Todo S, Lee RG, Madariaga JR, et al. Hepatic resection and transplantation for peripheral cholangiocarcinoma. J Am Coll Surg 1997; 185: 429-436 [Medline]

Chari RS, Anderson CA, Savarese DM. Treatment of cholangiocarcinoma II. UpDate. 2003 [Medline]

Chen JS, Jan YY, Lin YC, Wang HM, Chang WC, Liau CT. Weekly 24 h infusion of high-dose 5-fluorouracil and leucovorin in patients with biliary tract carcinomas. Anticancer Drugs 1998; 9: 393-397 [Medline]

Crane CH, Macdonald KO, Vauthey JN, Yehuda P, Brown T, Curley S, et al. Limitations of conventional doses of chemoradiation for unresectable biliary cancer. Int J Radiat Oncol Biol Phys 2002; 53: 969-974 [Medline]

Curado MP, Edwards B, Shin HR, Storm H, Ferlay J, Heanue M, et al. Cancer Incidence in Five Continents, Vol. IX. Lyon: IARC Scientific Publications No. 160. 2007 [Medline]

Ellis PA, Norman A, Hill A, O’Brien ME, Nicolson M, Hickish T, et al. Epirubicin, cisplatin and infusional 5-fluorouracil (5-FU) (ECF) in hepatobiliary tumours. Eur J Cancer 1995; 31A: 1594-1598 [Medline]

Fava G, Marzioni M, Benedetti A, Glaser S, DeMorrow S, Francis H, et al. Molecular pathology of biliary tract cancers. Cancer Lett 2007; 250: 155-167 [Medline]

Figueras J, Llado L, Valls C, Serrano T, Ramos E, Fabregat J, et al. Changing strategies in diagnosis and management of hilar cholangiocarcinoma. Liver Transpl 2000; 6: 786-794 [Medline]

Flickinger JC, Epstein AH, Iwatsuki S, Carr BI, Starzl TE. Radiation therapy for primary carcinoma of the extrahepatic biliary system. An analysis of 63 cases. Cancer 1991; 68: 289-294 [Medline]

Fong Y, Blumgart LH, Lin E, Fortner JG, Brennan MF. Outcome of treatment for distal bile duct cancer. Br J Surg 1996; 83: 1712-1715 [Medline]

Gebbia V, Giuliani F, Maiello E, Colucci G, Verderame F, Borsellino N, et al. Treatment of inoperable and/or metastatic biliary tree carcinomas with single-agent gemcitabine or in combination with levofolinic acid and infusional fluorouracil: results of a multicenter phase II study. J Clin Oncol 2001; 19: 4089-4091 [Medline]

Gores GJ. Cholangiocarcinoma: current concepts and insights. Hepatology 2003; 37: 961-969 [Medline]

Hann LE, Greatrex KV, Bach AM, Fong Y, Blumgart LH. Cholangiocarcinoma at the hepatic hilus: sonographic findings. AJR Am J Roentgenol 1997; 168: 985-989 [Medline]

Haswell-Elkins MR, Sithithaworn P, Mairiang E, Elkins DB, Wongratanacheewin S, Kaewkes S, et al. Immune responsiveness and parasite-specific antibody levels in human hepatobiliary disease associated with Opisthorchis viverrini infection. Clin Exp Immunol 1991; 84: 213-218 [Medline]

Hemming AW, Reed AI, Fujita S, Foley DP, Howard RJ. Surgical management of hilar cholangiocarcinoma. Ann Surg 2005; 241: 693-699 [Medline]

Hochwald SN, Burke EC, Jarnagin WR, Fong Y, Blumgart LH. Association of preoperative biliary stenting with increased postoperative infectious complications in proximal cholangiocarcinoma. Arch Surg 1999; 134: 261-266. [Medline]

Inal M, Akgul E, Aksungur E, Demiryurek H, Yagmur O. Percutaneous self-expandable uncovered metallic stents in malignant biliary obstruction. Complications, follow-up and reintervention in 154 patients. Acta Radiol 2003; 44: 139-146 [Medline]

Isa T, Tomita S, Nakachi A, Miyazato H, Shimoji H, Kusano T, et al. Analysis of microsatellite instability, K-ras gene mutation and p53 protein overexpression in intrahepatic cholangiocarcinoma. Hepatogastroenterology 2002; 49: 604-608 [Medline]

Jan YY, Jeng LB, Hwang TL, Wang CS, Chen MF, Chen TJ. Factors influencing survival after hepatectomy for peripheral cholangiocarcinoma. Hepatogastroenterology 1996; 43: 614-619 [Medline]

Jan YY, Yeh CN, Yeh TS, Chen TC. Prognostic analysis of surgical treatment of peripheral cholangiocarcinoma: two decades of experience at Chang Gung Memorial Hospital. World J Gastroenterol 2005; 11: 1779-1784 [Medline]

Jarnagin WR, Shoup M. Surgical management of cholangiocarcinoma. Semin Liver Dis 2004; 24: 189-199 [Medline]

Jonas S, Neuhaus P. The perspective of liver transplantation for cholangiocarcinoma. Liver Transpl 2007; 13: 1358-1361 [Medline]

Khan SA, Taylor-Robinson SD, Toledano MB, Beck A, Elliott P, Thomas HC. Changing international trends in mortality rates for liver, biliary and pancreatic tumours. J Hepatol 2002; 37: 806-813 [Medline]

Khan SA, Thomas HC, Davidson BR, Taylor-Robinson SD. Cholangiocarcinoma. Lancet 2005; 366: 1303-1314 [Medline]

Kim S, Kim SW, Bang YJ, Heo DS, Ha SW. Role of postoperative radiotherapy in the management of extrahepatic bile duct cancer. Int J Radiat Oncol Biol Phys 2002; 54: 414-419 [Medline]

Kim TW, Chang HM, Kang HJ, Lee JR, Ryu MH, Ahn JH, et al. Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced biliary cancer. Ann Oncol 2003; 14: 1115-1120 [Medline]

Klempnauer J, Ridder GJ, von Wasielewski R, Werner M, Weimann A, Pichlmayr R. Resectional surgery of hilar cholangiocarcinoma: a multivariate analysis of prognostic factors. J Clin Oncol 1997; 15: 947-954 [Medline]

Klinkenbijl JH, Jeekel J, Sahmoud T, van Pel R, Couvreur ML, Veenhof CH, et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg 1999; 230: 776-782 [Medline]

Knox JJ, Hedley D, Oza A, Feld R, Siu LL, Chen E, et al. Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial. J Clin Oncol 2005; 23: 2332-2338 [Medline]

Kubicka S, Rudolph KL, Tietze MK, Lorenz M, Manns M. Phase II study of systemic gemcitabine chemotherapy for advanced unresectable hepatobiliary carcinomas. Hepatogastroenterology 2001; 48: 783-789 [Medline]

Kubo S, Kinoshita H, Hirohashi K, Hamba H. Hepatolithiasis associated with cholangiocarcinoma. World J Surg 1995; 19: 637-641 [Medline]

Kuhn R, Hribaschek A, Eichelmann K, Rudolph S, Fahlke J, Ridwelski K. Outpatient therapy with gemcitabine and docetaxel for gallbladder, biliary, and cholangio-carcinomas. Invest New Drugs 2002; 20: 351-356 [Medline]

Lazaridis KN, Gores GJ. Cholangiocarcinoma. Gastroenterology 2005; 128: 1655-1667 [Medline]

Lipsett PA, Pitt HA, Colombani PM, Boitnott JK, Cameron JL. Choledochal cyst disease. A changing pattern of presentation. Ann Surg 1994; 220: 644-652 [Medline]

Martin RC, Klimstra DS, Schwartz L, Yilmaz A, Blumgart LH, Jarnagin W. Hepatic intraductal oncocytic papillary carcinoma. Cancer 2002; 95: 2180-2187 [Medline]

Mazhar D, Stebbing J, Bower M. Chemotherapy for advanced cholangiocarcinoma: what is standard treatment? Future Oncol 2006; 2: 509-514 [Medline]

McMasters KM, Tuttle TM, Leach SD, Rich T, Cleary KR, Evans DB, et al. Neoadjuvant chemoradiation for extrahepatic cholangiocarcinoma. Am J Surg 1997; 174: 605-608 [Medline]

Meyer CG, Penn I, James L. Liver transplantation for cholangiocarcinoma: results in 207 patients. Transplantation 2000; 69: 1633-1637 [Medline]

Nagino M, Kamiya J, Uesaka K, Sano T, Yamamoto H, Hayakawa N, et al. Complications of hepatectomy for hilar cholangiocarcinoma. World J Surg 2001; 25: 1277-1283 [Medline]

Nagorney DM, Donohue JH, Farnell MB, Schleck CD, Ilstrup DM. Outcomes after curative resections of cholangiocarcinoma. Arch Surg 1993; 128: 871-877 [Medline]

Nakeeb A, Pitt HA, Sohn TA, Coleman J, Abrams RA, Piantadosi S, et al. Cholangiocarcinoma. A spectrum of intrahepatic, perihilar, and distal tumors. Ann Surg 1996; 224: 463-473 [Medline]

Nakeeb A, Tran KQ, Black MJ, Erickson BA, Ritch PS, Quebbeman EJ, et al. Improved survival in resected biliary malignancies. Surgery 2002; 132: 555-563 [Medline]

Nimura Y, Hayakawa N, Kamiya J, Kondo S, Shionoya S. Hepatic segmentectomy with caudate lobe resection for bile duct carcinoma of the hepatic hilus. World J Surg 1990; 14: 535-543 [Medline]

Okuda K, Nakanuma Y, Miyazaki M. Cholangiocarcinoma: recent progress. Part 1: epidemiology and etiology. J Gastroenterol Hepatol 2002; 17: 1049-1055 [Medline]

Ortner ME, Caca K, Berr F, Liebetruth J, Mansmann U, Huster D, et al. Successful photodynamic therapy for nonresectable cholangiocarcinoma: a randomized prospective study. Gastroenterology 2003; 125: 1355-1363 [Medline]

Park SH, Park YH, Lee JN, Bang SM, Cho EK, Shin DB, et al. Phase II study of epirubicin, cisplatin, and capecitabine for advanced biliary tract adenocarcinoma. Cancer 2006; 106: 361-365 [Medline]

Parkin DM, Whelan SL, Ferlay J, Teppo L, Thomas DB. Cancer Incidence in Five Continents. Vol. VIII IARC Scientific Publications No. 155. Lyon: IARC Press. 2002 [Medline]

Patel T, Singh P. Cholangiocarcinoma: emerging approaches to a challenging cancer. Curr Opin Gastroenterol 2007; 23: 317-323 [Medline]

Patel T. Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology 2001; 33: 1353-1357 [Medline]

Patt YZ, Hassan MM, Aguayo A, Nooka AK, Lozano RD, Curley SA, et al. Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma. Cancer 2004; 101: 578-586 [Medline]

Patt YZ, Jones DV, Jr., Hoque A, Lozano R, Markowitz A, Raijman I, et al. Phase II trial of intravenous flourouracil and subcutaneous interferon alfa-2b for biliary tract cancer. J Clin Oncol 1996; 14: 2311-2315 [Medline]

Pitt HA, Nakeeb A, Abrams RA, Coleman J, Piantadosi S, Yeo CJ, et al. Perihilar cholangiocarcinoma. Postoperative radiotherapy does not improve survival. Ann Surg 1995; 221: 788-797 [Medline]

Qin XL, Wang ZR, Shi JS, Lu M, Wang L, He QR. Utility of serum CA19-9 in diagnosis of cholangiocarcinoma: in comparison with CEA. World J Gastroenterol 2004; 10: 427-432 [Medline]

Rea DJ, Heimbach JK, Rosen CB, Haddock MG, Alberts SR, Kremers WK, et al. Liver transplantation with neoadjuvant chemoradiation is more effective than resection for hilar cholangiocarcinoma. Ann Surg 2005; 242: 451-458 [Medline]

Saldinger PF, Blumgart LH. Resection of hilar cholangiocarcinoma–a European and United States experience. J Hepatobiliary Pancreat Surg 2000; 7: 111-114 [Medline]

Shaib Y, El Serag HB. The epidemiology of cholangiocarcinoma. Semin Liver Dis 2004b; 24: 115-125 [Medline]

Shaib YH, Davila JA, McGlynn K, El Serag HB. Rising incidence of intrahepatic cholangiocarcinoma in the United States: a true increase? J Hepatol 2004a; 40: 472-477 [Medline]

Sharma MP, Ahuja V. Aetiological spectrum of obstructive jaundice and diagnostic ability of ultrasonography: a clinician’s perspective. Trop Gastroenterol 1999; 20: 167-169 [Medline]

Shimoda M, Farmer DG, Colquhoun SD, Rosove M, Ghobrial RM, Yersiz H, et al. Liver transplantation for cholangiocellular carcinoma: analysis of a single-center experience and review of the literature. Liver Transpl 2001; 7: 1023-1033 [Medline]

Shirabe K, Shimada M, Tsujita E, Aishima S, Maehara S, Tanaka S, et al. Prognostic factors in node-negative intrahepatic cholangiocarcinoma with special reference to angiogenesis. Am J Surg 2004; 187: 538-542 [Medline]

Siqueira E, Schoen RE, Silverman W, Martin J, Rabinovitz M, Weissfeld JL, et al. Detecting cholangiocarcinoma in patients with primary sclerosing cholangitis. Gastrointest Endosc 2002; 56: 40-47 [Medline]

Sirica AE. Cholangiocarcinoma: molecular targeting strategies for chemoprevention and therapy. Hepatology 2005; 41: 5-15 [Medline]

Slattery JM, Sahani DV. What is the current state-of-the-art imaging for detection and staging of cholangiocarcinoma? Oncologist 2006; 11: 913-922 [Medline]

Su CH, Tsay SH, Wu CC, Shyr YM, King KL, Lee CH, et al. Factors influencing postoperative morbidity, mortality, and survival after resection for hilar cholangiocarcinoma. Ann Surg 1996; 223: 384-394 [Medline]

Sudan D, DeRoover A, Chinnakotla S, Fox I, Shaw B, Jr., McCashland T, et al. Radiochemotherapy and transplantation allow long-term survival for nonresectable hilar cholangiocarcinoma. Am J Transplant 2002; 2: 774-779 [Medline]

Swierczynski SL, Maitra A, Abraham SC, Iacobuzio-Donahue CA, Ashfaq R, Cameron JL, et al. Analysis of novel tumor markers in pancreatic and biliary carcinomas using tissue microarrays. Hum Pathol 2004; 35: 357-366 [Medline]

Takada T, Amano H, Yasuda H, Nimura Y, Matsushiro T, Kato H, et al. Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma. Cancer 2002; 95: 1685-1695 [Medline]

Taylor-Robinson SD, Toledano MB, Arora S, Keegan TJ, Hargreaves S, Beck A, et al. Increase in mortality rates from intrahepatic cholangiocarcinoma in England and Wales 1968-1998. Gut 2001; 48: 816-820 [Medline]

Todoroki T, Ohara K, Kawamoto T, Koike N, Yoshida S, Kashiwagi H, et al. Benefits of adjuvant radiotherapy after radical resection of locally advanced main hepatic duct carcinoma. Int J Radiat Oncol Biol Phys 2000; 46: 581-587 [Medline]

Tsuzuki T, Ogata Y, Iida S, Nakanishi I, Takenaka Y, Yoshii H. Carcinoma of the bifurcation of the hepatic ducts. Arch Surg 1983; 118: 1147-1151 [Medline]

UICC. UICC (International Union Against Cancer). TNM classification of malignant tumours. Sobin LH, Wittekind Ch, editors. 6th ed. New York, Chichester, weinheim, Brisbane, Singapore, Toronto: Wiley-Liss. 2002 [Medline]

Urego M, Flickinger JC, Carr BI. Radiotherapy and multimodality management of cholangiocarcinoma. Int J Radiat Oncol Biol Phys 1999; 44: 121-126 [Medline]

Weinbren K, Mutum SS. Pathological aspects of cholangiocarcinoma. J Pathol 1983; 139: 217-238 [Medline]

Yeh CN, Jan YY, Chen MF. Influence of age on surgical treatment of peripheral cholangiocarcinoma. Am J Surg 2004; 187: 559-563 [Medline]

Yeh TS, Jan YY, Tseng JH, Chiu CT, Chen TC, Hwang TL, et al. Malignant perihilar biliary obstruction: magnetic resonance cholangiopancreatographic findings. Am J Gastroenterol 2000; 95: 432-440 [Medline]

Zhang Y, Uchida M, Abe T, Nishimura H, Hayabuchi N, Nakashima Y. Intrahepatic peripheral cholangiocarcinoma: comparison of dynamic CT and dynamic MRI. J Comput Assist Tomogr 1999; 23: 670-677 [Medline]


Dr. Giordano Beretta (Associate Editor)
Ospedale Sant’Orsola-Fatebenefratelli – Brescia, Italy.

Dr. Gemma Gatta (Consultant)
Istituto Nazionale Tumori – Milan, Italy

Prof. Volker Heinemann (Reviewer)
Klinikum der Universitaet Muenchen-Grosshadem, Germany

Dr. Stefania Mosconi (Author)
Ospedali Riuniti – Bergamo, Italy

Dr. Luca Tondulli (Author)
Ospedale Sant’Orsola-Fatebenefratelli – Brescia, Italy